Efficacy of NOAC reversal agent confirmed
12th July 2017
Doctors can now be confident that at least one non-vitamin K oral anticoagulant (NOAC) has an effective antidote to prevent potential bleeds.
According to the final results from the industry-funded RE-VERSE AD trial, idarucizumab leads to the immediate reversal of the anticoagulant effect of dabigatran in patients in emergency situations.
The findings from the study of